Objective
to compare the 7 year clinical outcomes of a first generation sirolimus-eluting stent (SES) with a new generation everolimus-eluting stent (EES)
Study
prospective multicentre randomised trial (non-inferiority)
Population
all-comers
Endpoints
any target lesion revascularisation at 7 years


Conclusion
the need for target lesion revascularisation was, during a follow-up duration of 7 years, not different with new generation EES compared to first generation SES
Shiomi et al. J Am Coll Cardiol Intv. 2019;12:637-47